No Image Available
Description
ZyVac® MMR is a live attenuated vaccine developed by Zydus Lifesciences Limited to provide immunity against measles, mumps, and rubella.
Target Diseases
- measles
- mumps
- and rubella.
Dosage Schedule
A single 0.5 ml dose administered subcutaneously. The Indian Academy of Pediatrics recommends two doses: the first at 9–12 months and the second at 4–6 years.
Possible Side Effects
- Common side effects may include mild pain and tenderness at the injection site
- fever
- and rash. These symptoms usually resolve within a few days. Serious adverse reactions are rare.
Contraindications
- Individuals with known hypersensitivity to any component of the vaccine
- including egg protein or gelatin
- should not receive ZyVac® MMR. It is also contraindicated in pregnant women and individuals with severe immunosuppression.
Additional Information
- ZyVac® MMR contains the Edmonston Zagreb strain for measles
- Hoshino strain for mumps
- and RA 27/3 strain for rubella. Clinical trials have demonstrated its safety and immunogenicity
- with high seroconversion rates for all three components.
Storage Requirements
- The vaccine should be stored in a refrigerator at 2–8°C and protected from light. Do not freeze.
